Regulating MHC expression for cellular therapeutics

Transfusion

Volumn 47, Issue 1, 2007, Pages 18-27

  Figueiredo, Constança ^a   Horn, Peter A ^a   Blasczyk, Rainer ^a,b   Seltsam, Axel ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Institute for Transfusion Medicine   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; HLA ANTIGEN; HLA ANTIGEN CLASS 1; LENTIVIRUS VECTOR; SHORT HAIRPIN RNA;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL THERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOLYSIS; EMBRYO; GENE EXPRESSION; GENE INDUCTION; GENE SILENCING; GENETIC TRANSDUCTION; HELA CELL; HUMAN; HUMAN CELL; IMMUNOREGULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MONOCYTE; NATURAL KILLER CELL; RNA INTERFERENCE; RNA SEQUENCE;

CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TRANSFORMED; CELL PROLIFERATION; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY TESTS, IMMUNOLOGIC; FEASIBILITY STUDIES; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GRAFT REJECTION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; KILLER CELLS, NATURAL; LENTIVIRUS; MONOCYTES; RNA INTERFERENCE; STEM CELL TRANSPLANTATION;

EID: 33845731330     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01059.x     Document Type: Article

References (40)

1. He CW, Liu F, Zhang YF, et al. Inducing apoptosis of human nasopharyngeal carcinoma cell line CNE-2Z by bcl-x(L) short hairpin RNA. Ai Zheng 2005;24:646-52.
2. Leung RK, Whittaker PA. RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol Ther 2005;107:222-39.
3. Miller VM, Gouvion CM, Davidson BL, Paulson HL. Targeting Alzheimer's disease genes with RNA interference: an efficient strategy for silencing mutant alleles. Nucleic Acids Res 2004;32:661-8.
4. Pardridge WM. Intravenous, non-viral RNAi gene therapy of brain cancer. Expert Opin Biol Ther 2004;4:1103-13.
5. Ishizuya-Oka A. Epithelial-connective tissue cross-talk is essential for regeneration of intestinal epithelium. J Nippon Med Sch 2005;72:13-8.
6. Perrier AL, Tabar V, Barberi T, et al. Derivation of midbrain dopamine neurons from human embryonic stem cells. Proc Natl Acad Sci U S A 2004;101:12543-8.
7. Tran SD, Pillemer SR, Dutra A, et al. Differentiation of human bone marrow-derived cells into buccal epithelial cells in vivo: a molecular analytical study. Lancet 2003;361:1084-8.
8. Ahsan T, Nerem RM. Bioengineered tissues: the science, the technology, and the industry. Orthod Craniofac Res 2005;8:134-40.
9. Shufaro Y, Reubinoff BE. Therapeutic applications of embryonic stem cells. Best Pract Res Clin Obstet Gynaecol 2004;18:909-27.
10. Krensky AM. The HLA system, antigen processing and presentation. Kidney Int Suppl 1997;58:S2-7.
11. Hernandez-Fuentes MP, Baker RJ, Lechler RI. The alloresponse. Rev Immunogenet 1999;1:282-96.
12. Hansen JA. T-cell alloreactivity in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005;11(2 Suppl 2):24-7.
13. Strom TB, Field LJ, Ruediger M. Allogeneic stem cells, clinical transplantation, and the origins of regenerative medicine. Transplant Proc 2001;33:3044-9.
14. Down JD, White-Scharf ME. Reprogramming immune responses: enabling cellular therapies and regenerative medicine. Stem Cells 2003;21:21-32.
15. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001;15:188-200.
16. Saito Y, Dzik S. Gene knockdown: RNA-interference is coming of age. Transfusion 2005;45:111-4.
17. An DS, Xie Y, Mao SH, et al. Efficient lentiviral vectors for short hairpin RNA delivery into human cells. Hum Gene Ther 2003;14:1207-12.
18. Li M, Rossi JJ. Lentiviral vector delivery of siRNA and shRNA encoding genes into cultured and primary hematopoietic cells. Methods Mol Biol 2005;309:261-72.
19. Paddison PJ, Caudy AA, Bernstein E, et al. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 2002;16:948-58.
20. Beyer F, Doebis C, Busch A, et al. Decline of surface MHC I by adenoviral gene transfer of anti-MHC I intrabodies in human endothelial cells - new perspectives for the generation of universal donor cells for tissue transplantation. J Gene Med 2004;6:616-23.
21. Busch A, Marasco WA, Doebis C, et al. MHC class I manipulation on cell surfaces by gene transfer of anti-MHC class I intrabodies - a tool for decreased immunogenicity of allogeneic tissue and cell transplants. Methods 2004;34:240-9.
22. Mhashilkar AM, Doebis C, Seifert M, et al. Intrabody-mediated phenotypic knockout of major histocompatibility complex class I expression in human and monkey cell lines and in primary human keratinocytes. Gene Ther 2002;9:307-19.
23. Figueiredo C, Seltsam A, Blasczyk R. HLA silencing by RNAi-mediated transcript targeting. Genes Immunity 2004;5(Suppl):6.
24. Figueiredo CS, Seltsam A, Blasczyk R. Class-, gene- and group-specific HLA silencing by lentiviral shRNA delivery. J Mol Med 2006;84:425-37.
25. Gonzalez S, Castanotto D, Li H, et al. Amplification of RNAi - targeting HLA mRNAs. Mol Ther 2005;11:811-8.
26. Wiznerowicz M, Trono D. Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J Virol 2003;77:8957-61.
27. Terasaki P. Microdoplet testing for HLA-A, -B, -C and D antigens. Am J Clin Pathol 1978;69:103-20.
28. Jedema I, van der Werff NM, Barge RM, et al. New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. Blood 2004;103:2677-82.
29. Beckman EM, Porcelli SA, Morita CT, et al. Recognition of a lipid antigen by CD1-restricted alpha beta+ T cells. Nature 1994;372:691-4.
30. Abbas-Terki T, Blanco-Bose W, Deglon N, et al. Lentiviral-mediated RNA interference. Hum Gene Ther 2002;13:2197-201.
31. Boden D, Pusch O, Lee F, et al. Efficient gene transfer of HIV-1-specific short hairpin RNA into human lymphocytic cells using recombinant adeno-associated virus vectors. Mol Ther 2004;9:396-402.
32. Scherr M, Battmer K, Ganser A, Eder M. Modulation of gene expression by lentiviral-mediated delivery of small interfering RNA. Cell Cycle 2003;2:251-7.
33. Clark R, Kupper T. Old meets new: the interaction between innate and adaptive immunity. J Invest Dermatol 2005;125:629-37.
34. Bradley JA, Bolton EM, Pettigrew G. Monitoring T cell alloreactivity after organ transplantation. Clin Exp Immunol 2005;142:229-32.
35. Moll S, Pascual M. Humoral rejection of organ allografts. Am J Transplant 2005;5:2611-8.
36. Olszewski WL. Innate immunity processes in organ allografting - their contribution to acute and chronic rejection. Ann Transplant 2005;10:5-9.
37. Varnavidou-Nicolaidou A, Iniotaki-Theodoraki AG, Doxiadis II, et al. Expansion of humoral donor-specific alloreactivity after renal transplantation correlates with impaired graft outcome. Hum Immunol 2005;66:985-8.
38. Waller EK. Cellular immunotherapy and cancer. Semin Oncol 2004;31(2 Suppl 4):87-90.
39. Demanet C, Mulder A, Deneys V, et al. Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack? Blood 2004;103:3122-30.
40. Carbone E, Neri P, Mesuraca M, et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 2005;105:251-8.